Takhzyro (lanadelumab-flyo) is a biologic medicine used to prevent hereditary angioedema (HAE) attacks in people who are 2 years or older. During an HAE attack, swelling under the skin happens in ...
Even if you’re doing everything you can to avoid an episode of hereditary angioedema (HAE) — dodging injuries, preventing respiratory illnesses, taking medication — it’s not always possible to ward ...
Deucrictibant significantly improved the time to onset of symptom relief, defined as PGI-C of at least “a little better”, compared with placebo (1.28 vs >12 hours). Topline data were announced from a ...
Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001) All secondary efficacy endpoints met (p<0.0001), including End of ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European ...
The U.S. Food and Drug Administration (FDA) on Friday approved BioCryst Pharmaceuticals Inc.’s (NASDAQ: BCRX) New Drug Application (NDA) for the use of an oral pellet formulation of once-daily ...
A person with hereditary angioedema (HAE) should seek emergency care during an HAE episode if they are having difficulty breathing or experiencing swelling of the tongue or throat, which could lead to ...
HAE is a rare genetic disorder that causes recurrent, severe swelling in the skin, face, limbs, and internal organs, including the airway and gastrointestinal tract. The study enrolled a total of 134 ...
RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (BCRX) (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its ...
The EC’s approval was based on results from the phase 3 OASIS-HAE study. The study showed that an 80mg dose of Dawnzera every ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results